Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
Current Hematologic Malignancy Reports
Erschienen in: Current Hematologic Malignancy Reports 4/2017

18.08.2017 | CART and Immunotherapy (M Ruella, Section Editor)

Novel Immunotherapies for Multiple Myeloma

verfasst von: Mattia D’Agostino, Mario Boccadoro, Eric L. Smith

Erschienen in: Current Hematologic Malignancy Reports | Ausgabe 4/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

The treatment landscape of multiple myeloma is rapidly changing; however, despite improvement in patients’ survival, it still remains a largely incurable disease. One hallmark of myeloma is substantial immune dysfunction leading to an increased infection rate and the inability of immune surveillance to detect neoplastic cells. Here, we critically analyze clinical approaches to harness the immune system to overcome this defect with a focus on antibody based and adoptive cellular therapies.

Recent Findings

Clinical trials exploring these immunotherapies to treat myeloma are now well underway and show promising results. In relapsed myeloma, monoclonal antibodies directed against plasma cell antigens and immune checkpoints have already shown substantial efficacy. In parallel, trials of adoptive cellular therapy have exciting promise in myeloma, having induced dramatic responses in a handful of early study participants.

Summary

Taken together, immunotherapeutic approaches hold enormous potential in the field of multiple myeloma and in the near future can be combined with or even replace the current standard of care.
Literatur
1.
Howlader N, Noone AM, Krapcho M, Garshell J, Neyman N, Altekruse SF, et al. SEER cancer statistics review, 1975–2010 - previous version - SEER cancer statistics review. Bethesda: National Cancer Institute; 2010.
2.
Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2014;28(5):1122–8.CrossRefPubMed
3.
Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111(5):2516–20.CrossRefPubMedPubMedCentral
4.
Papadas A, Asimakopoulos F. Mechanisms of resistance in multiple myeloma. Berlin Heidelberg: Springer; 2017. p. 1–38.
5.
Tete SM, Bijl M, Sahota SS, Bos NA. Immune defects in the risk of infection and response to vaccination in monoclonal gammopathy of undetermined significance and multiple myeloma. Front Immunol. Frontiers Media SA. 2014;5:257.
6.
Kristinsson SY, Tang M, Pfeiffer RM, Björkholm M, Goldin LR, Blimark C, et al. Monoclonal gammopathy of undetermined significance and risk of infections: a population-based study. Haematologica. Ferrata Storti Foundation. 2012;97(6):854–8.CrossRefPubMedPubMedCentral
7.
Robertson JD, Nagesh K, Jowitt SN, Dougal M, Anderson H, Mutton K, et al. Immunogenicity of vaccination against influenza, Streptococcus Pneumoniae and Haemophilus influenzae type B in patients with multiple myeloma. Br J Cancer. 2000;82(7):1261–5.CrossRefPubMedPubMedCentral
8.
Rawstron AC, Davies FE, Owkn RG, English A, Pratt G, Child JA, et al. B-lymphocyte suppression in multiple myeloma is a reversible phenomenon specific to normal B-cell progenitors and plasma cell precursors. Br J Haematol. Blackwell Publishers. 1998;100(1):176–83.CrossRefPubMed
9.
Katzmann JA, Clark R, Kyle RA, Larson DR, Therneau TM, Melton LJ, et al. Suppression of uninvolved immunoglobulins defined by heavy/light chain pair suppression is a risk factor for progression of MGUS. Leukemia. NIH Public. Access. 2013;27(1):208–12.CrossRefPubMed
10.
Frassanito MA, Cusmai A, Dammacco F. Deregulated cytokine network and defective Th1 immune response in multiple myeloma. Clin Exp Immunol. 2001 Aug;125(2):190–7.CrossRefPubMedPubMedCentral
11.
Brown RD, Pope B, Murray A, Esdale W, Sze DM, Gibson J, et al. Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-??1 and interleukin-10. Blood. 2001;98(10):2992–8.CrossRefPubMed
12.
Jurisic V, Srdic T, Konjevic G, Markovic O, Colovic M. Clinical stage-depending decrease of NK cell activity in multiple myeloma patients. Med Oncol. 2007;24(3):312–7.CrossRefPubMed
13.
Pratt G, Goodyear O, Moss P. Immunodeficiency and immunotherapy in multiple myeloma. Br J Haematol. 2007;138:563–79.
14.
15.
Yousef S, Marvin J, Steinbach M, Langemo A, Kovacsovics T, Binder M, et al. Immunomodulatory molecule PD-L1 is expressed on malignant plasma cells and myeloma-propagating pre-plasma cells in the bone marrow of multiple myeloma patients. Blood Cancer J. 2015;5(3):e285.CrossRefPubMedPubMedCentral
16.
17.
Smith E, Devlin SM, Kosuri S, Orlando E, Landau H, Lesokhin AM, et al. CD34-selected allogeneic hematopoietic stem cell transplantation for patients with relapsed, high-risk multiple myeloma. Biol Blood Marrow Transplant. 2016;22(2):258–67. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​26325439. Accessed 12 Apr 2017.
18.
19.
20.
Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer Nature Publishing Group. 2012;12(4):278–87.CrossRef
21.
De Donk NWCJ V, Moreau P, Plesner T, Palumbo A, Gay F, Laubach JP, et al. Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma. Blood. 2016;127:681–95.
22.
Tai Y-T, Anderson KC. Antibody-based therapies in multiple myeloma. Bone Marrow Res. 2011;2011 (Figure 1):1–14.CrossRef
23.
Lokhorst HM, Plesner T, Laubach JP, Nahi H, Gimsing P, Hansson M, et al. Targeting CD38 with Daratumumab monotherapy in multiple myeloma. N Engl J Med. 2015 Sep;373(13):1207–19.CrossRefPubMed
24.
Lonial S, Weiss BM, Usmani SZ, Singhal S, Chari A, Bahlis NJ, et al. Phase II study of daratumumab (DARA) monotherapy in patients with >= 3 lines of prior therapy or double refractory multiple myeloma (MM): 54767414MMY2002 (Sirius). ASCO Meet Abstr. 2015;33(18_suppl):LBA 8512.
25.
•• Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, et al. Daratumumab, Bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375(8):754–66. Potentially practice-changing data in RRMM patients treated with Daratumumab/Bortezomib-based backbone treatment.CrossRefPubMed
26.
•• Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ, et al. Daratumumab, Lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375(14):1319–31. Massachusetts Medical Society. Potentially practice-changing data in RRMM patients treated with Daratumumab/Lenalidomide-based backbone treatment.CrossRefPubMed
27.
Martin TG, Hsu K, Strickland SA, Glenn MJ, Mikhael J, Charpentier E. A phase I trial of SAR650984, a CD38 monoclonal antibody, in relapsed or refractory multiple myeloma. J Clin Oncol. 2014;32:abstr 8532.
28.
Vij R, Lendvai N, Martin TG, Baz RC, Campana F, Mazuir F, Charpentier E. Benson DM. et al. A phase Ib dose escalation trial of isatuximab (SAR650984, anti-CD38 mAb) plus lenalidomide and dexamethasone (Len/Dex) in relapsed/refractory multiple myeloma (RRMM): Interim results from two new dose cohorts. J Clin Oncol. 2016;34:15_suppl, 8009–8009.
29.
Mikhael J, Richardson PG, Usmani Z, Raje N, Bensinger W, Kanagavel D, et al. A phase Ib study of isatuximab in combination with pomalidomide (Pom) and dexamethasone (Dex) in relapsed/refractory multiple myeloma (RRMM). 2017 ASCO Annual Meeting Abstracts. JCO. (2017); 35 (suppl; abstr 8007).
30.
Raab MS, Chatterjee M, Goldschmidt H, Agis H, Blau I, Einsele H, Engelhardt M. Ferstl B. Gramatzki M. öllig CR. Weisel K. Jarutat T. Weinelt D. Endell J. Boxhammer R. Peschel C.et al. A phase I/IIa study of the CD38 antibody MOR202 alone and in combination with pomalidomide or lenalidomide in patients with relapsed or refractory multiple myeloma. Blood 2016;128:1152.
31.
Zonder JA, Mohrbacher AF, Singhal S, Van Rhee F, Bensinger WI, Ding H, et al. A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma. Blood. 2012;120(3):552–9.CrossRefPubMedPubMedCentral
32.
Jakubowiak A, Offidani M, Brigitte P, La Rubia JD, Garderet L, Laribi K, et al. Randomized phase 2 study : elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM. Blood. 2016;127(23):2833–41.CrossRefPubMedPubMedCentral
33.
• Lonial S, Dimopoulos M, Palumbo A, White D, Grosicki S, Spicka I, et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med. 2015;373(7):621–31. Massachusetts Medical Society. A large phase III randomized trial demonstrating the advantage of Elotuzumab addition to lenalidomide-dexamethasone treatment in RRMM patients. Elotuzumab is not active as single agent in MM, however this study clearly demonstrates the clinical synergy of Elotuzumab and IMiDs.CrossRefPubMed
34.
Lesokhin AM, Ansell SM, Armand P, Scott EC, Halwani A, Gutierrez M, et al. Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase ib study. J Clin Oncol. 2016;34(23):2698–704.CrossRefPubMedPubMedCentral
35.
Mateos M-V, Orlowski RZ, Siegel DSD, Reece DE, Moreau P, Ocio EM, Shah JJ, Rodríguez-Otero P, Munshi NC, Avigan D, Ge JY, Marinello PM, et al. Pembrolizumab in combination with lenalidomide and low-dose dexamethasone for relapsed/refractory multiple myeloma (RRMM): Final efficacy and safety analysis. J Clin Oncol. 2016 34:15_suppl, 8010-8010.
36.
• Badros AZ, Hyjek E, Ma N, Lesokhin AM, Rapoport AP, Kocoglu MH, Lederer E, Philip S, Lesho P, Johnson A, Dell C, Goloubeva O, Singh B, et al. Pembrolizumab in combination with pomalidomide and dexamethasone for relapsed/refractory multiple myeloma (RRMM). Blood. 2016;128(22). A phase II study on higly preatretad patients with an high percentace of PI and IMiDs double-refractory patients showing benefit from PD-1 directed therapy associated with pomalidomide backbone treatment.
37.
Malavasi F, Deaglio S, Funaro A, Ferrero E, Horenstein AL, Ortolan E, et al. Evolution and function of the ADP ribosyl cyclase/CD38 gene family in physiology and pathology. Physiol Rev. 2008;88(3):841–86.CrossRefPubMed
38.
van de Donk NWCJ, Janmaat ML, Mutis T, Lammerts van Bueren JJ, Ahmadi T, Sasser AK, et al. Monoclonal antibodies targeting CD38 in hematological malignancies and beyond. Immunol Rev. 2016) 270(1):95–112. doi:10.​1111/​imr.​12389. Accessed 10 Jul 2017.
39.
Lin P, Owens R, Tricot G, Wilson CS. Flow cytometric Immunophenotypic analysis of 306 cases of multiple myeloma. Am J Clin Pathol. 2004;121(4):482–8.CrossRefPubMed
40.
Chapuy CI, Nicholson RT, Aguad MD, Chapuy B, Laubach JP, Richardson PG, et al. Resolving the daratumumab interference with blood compatibility testing. Transfusion. 2015) 55(6 Pt 2):1545–54. doi:10.​1111/​trf.​13069. Accessed 10 Jul 2017.
41.
Plesner T, Arkenau H-T, Lokhorst HM, Gimsing P, Krejcik J, Lemech C, et al. Safety and efficacy of Daratumumab with Lenalidomide and dexamethasone in relapsed or relapsed, refractory multiple myeloma. Blood. 2014;124(21):84.
42.
Mateos MV, Moreau P, Comenzo R, Bladé J, Benboubker L, de la Rubia J et al. An open-label, multicenter, phase 1b study of daratumumab in combination with oomalidomide-dexamethasone and with backbone regimens in patients with multiple myeloma. 20th Congress of European Hematology Association (EHA), Vienna, Austria, 11–14 June 2015 (abstract P275).
43.
Deckert J, Wetzel MC, Bartle LM, Skaletskaya A, Goldmacher VS, Vallée F, et al. SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies. Clin Cancer Res. 2014;20(17):4574–83.CrossRefPubMed
44.
Mikhael J, Richardson PG, Usmani Z, Raje N, Bensinger W, Kanagavel D, et al. A phase Ib study of isatuximab in combination with pomalidomide (Pom) and dexamethasone (Dex) in relapsed/refractory multiple myeloma (RRMM). 2017 ASCO Annual Meeting Abstracts. JCO. (2017); 35 (suppl; abstr 8007).
45.
Tawara T, Hasegawa K, Sugiura Y, Harada K, Miura T, Hayashi S, et al. Complement activation plays a key role in antibody-induced infusion toxicity in monkeys and rats. J Immunol. 2008;180(4):2294–8.CrossRefPubMed
46.
Veillette A, Guo H. CS1, a SLAM family receptor involved in immune regulation, is a therapeutic target in multiple myeloma. Crit Rev Oncol/Hematol. 2013;88:168–77.
47.
Hsi ED, Steinle R, Balasa B, Szmania S, Draksharapu A, Shum BP, et al. CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clin Cancer Res. 2008;14(9):2775–84.CrossRefPubMedPubMedCentral
48.
Collins SM, Bakan CE, Swartzel GD, Hofmeister CC, Efebera YA, Kwon H, et al. Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC. Cancer Immunol Immunother. 2013;62(12):1841–9.CrossRefPubMedPubMedCentral
49.
Tai Y-T, Dillon M, Song W, Leiba M, Li X-F, Burger P, et al. Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood. 2008) 112(4):1329–37. doi:10.​1182/​blood-2007-08-107292. Accessed 10 Jul 2017.
50.
FDA. FDA approves Empliciti, a new immune-stimulating therapy to treat multiple myeloma. FDA News release. (2015).
51.
52.
Liu J, Hamrouni A, Wolowiec D, Coiteux V, Kuliczkowski K, Hetuin D, et al. Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-γ and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway. Blood. 2007;110(1):296–304.CrossRefPubMed
53.
Tamura H, Ishibashi M, Yamashita T, Tanosaki S, Okuyama N, Kondo A, et al. Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma. Leukemia. Nature Publishing Group. 2012;27(2):464–72.CrossRefPubMed
54.
Wang L, Wang H, Chen H, Wang W, Chen X-Q, Geng Q-R, et al. Serum levels of soluble programmed death ligand 1 predict treatment response and progression free survival in multiple myeloma. Oncotarget. 2015;6(38):41228–36.CrossRefPubMedPubMedCentral
55.
Paiva B, Azpilikueta A, Puig N, Ocio EM, Sharma R, Oyajobi BO, et al. PD-L1/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma. Leukemia. 2015;29(10):2110–3.CrossRefPubMed
56.
Hallett WHD, Jing W, Drobyski WR, Johnson BD. Immunosuppressive effects of multiple myeloma are overcome by PD-L1 blockade. Biol Blood Marrow Transplant. 2011;17(8):1133–45.CrossRefPubMed
57.
Görgün G, Samur MK, Cowens KB, Paula S, Bianchi G, Anderson JE, et al. Lenalidomide enhances immune checkpoint blockade-induced immune response in multiple myeloma. Clin Cancer Res. 2015;21(20):4617–8.CrossRef
58.
Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015; 373:23–34.
59.
Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, et al. PD-1 blockade with Nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med. 2014;372(4):141206100011003.
60.
Benson DM. Checkpoint inhibition in myeloma. ASH Educ Progr B. 2016;2016(1):528–33.
61.
Heffner LT, Jagannath S, Zimmerman TM, Lee KP, Rosenblatt J, Lonial S, et al. BT062, an antibody-drug conjugate directed against CD138, given weekly for 3 weeks in each 4 week Cycle : safety and further evidence of clinical activity. Am Soc Hematol Annu Meet Proc. 2012;120(21):653.
62.
Chanan-Khan A, Wolf AJL, Garcia J, Gharibo M, Jagannath S, Manfredi D, et al. Efficacy analysis from phase I study of Lorvotuzumab Mertansine ( IMGN901 ) used as monotherapy in patients with heavily pre-treated CD56-positive multiple myeloma case Description : patient 0226. Blood. 2010;116(December):2010.
63.
Kelly KR, Chanan-Khan A, Heffner LT, Somlo G, Siegel DS, Zimmerman T, et al. Indatuximab Ravtansine (BT062) in combination with Lenalidomide and low-dose dexamethasone in patients with relapsed and/or refractory multiple myeloma: clinical activity in patients already exposed to Lenalidomide and Bortezomib. Blood. 2014;124(21):4736.
64.
Berdeja JG, Ailawadhi S, Weitman SD, Zildjian S, O’Leary JJ, O’Keeffe J, et al. Phase I study of lorvotuzumab mertansine (LM, IMGN901) in combination with lenalidomide (Len) and dexamethasone (Dex) in patients with CD56-positive relapsed or relapsed/refractory multiple myeloma (MM). ASCO Meet Abstr. 2011;29(15_suppl):8013.
65.
Kumar SK, Anderson KC. Immune therapies in multiple myeloma. Clin Cancer Res. 2016;22(22):5453–60.CrossRefPubMed
66.
67.
68.
Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2014;385(9967):517–28. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​25319501. Accessed 14 Oct 2014.
69.
70.
•• Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, Cowell LG, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med. 2013;5(177):177ra38. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​23515080. Accessed 25 Aug 2016. First report of the dramatic efficacy of CD19 targeted CAR T cell therapy in B-ALL.
71.
• Garfall AL, Maus MV, Hwang W-T, Lacey SF, Mahnke YD, Melenhorst JJ, et al. Chimeric antigen receptor T cells against CD19 for multiple myeloma. N Engl J Med. 2015;373(11):1040–7. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​26352815. Accessed 10 Jul 2017. Report of CD19 targeted CAR T cell therapy for MM.
72.
73.
74.
75.
76.
77.
78.
•• Ali SA, Shi V, Maric I, Wang M, Stroncek DF, Rose JJ, et al. T cells expressing an anti-B-cell-maturation-antigen chimeric antigen receptor cause remissions of multiple myeloma. Blood. 2016; Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​27412889. Accessed 04 Apr 2017. Initial demonstration of the potential for BCMA targeted CAR T cell therapy to eradiacte large disease burden in patients with MM.
79.
80.
Berdeja JG, Lin Y, Raje NS, Siegel DSD, Munshi NC, Liedtke M, et al. First-in-human multicenter study of bb2121 anti-BCMA CAR T-cell therapy for relapsed/refractory multiple myeloma: updated results. J Clin Oncol. American Society of Clinical Oncology. 2017;35(15_suppl):3010. doi:10.​1200/​JCO.​2017.​35.​15_​suppl.​3010.
81.
Xiaohu FF, Zhao W, Liu J, He A, Chen Y, Cao X, et al. Durable remissions with BCMA-specific chimeric antigen receptor (CAR)-modified T cells in patients with refractory/relapsed multiple myeloma. J Clin Oncol. 2017) American Society of Clinical Oncology. 35(18_suppl):LBA3001. doi:10.​1200/​JCO.​2017.​35.​18_​suppl.​LBA3001. Accessed 10 Jul 2017.
82.
Cohen AD, Garfall AL, Stadtmauer EA, Lacey SF, Lancaster E, Vogl DT, et al. B-cell maturation antigen (BCMA)-specific chimeric antigen receptor T cells (CART-BCMA) for multiple myeloma (MM): initial safety and efficacy from a phase I study. Blood. 2016 128:1147. Available from: http://​www.​bloodjournal.​org/​content/​128/​22/​1147. Accessed 4 Apr 2017.
83.
Turtle CJ, Hanafi L-A, Berger C, Hudecek M, Pender B, Robinson E, et al. Immunotherapy of non-Hodgkins lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells. Sci Transl Med. 2016;8(355):355ra116. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​27605551. Accessed 4 Apr 2017.
84.
Ali SA, Shi V, Wang M, Stroncek D, Maric I, Brudno JN, et al. Remissions of multiple myeloma during a first-in-humans clinical trial of T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor. Blood. 2015;126(23):LBA-1. American Society of Hematology. Available from: http://​www.​bloodjournal.​org/​content/​126/​23/​LBA-1.​abstract. Accessed 21 Feb 2016.
85.
Cameron BJ, Gerry AB, Dukes J, Harper JV, Kannan V, Bianchi FC, et al. Identification of a titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells. Sci Transl Med. 2013;5(197):197ra103. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​23926201. Accessed 4 Apr 2017.
86.
87.
•• Rapoport AP, Stadtmauer EA, Binder-Scholl GK, Goloubeva O, Vogl DT, Lacey SF, et al. NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Nat Med. 2015;21(8):914–21. Available from: http://​www.​nature.​com/​doifinder/​10.​1038/​nm.​3910. Accessed 4 Apr 2017. Report of sTCR engineered T cells for the treatment of MM.
88.
Jahn L, Hombrink P, Hagedoorn RS, Kester MGD, Van Der Steen DM, Rodriguez T, et al. TCR-based therapy for multiple myeloma and other B-cell malignancies targeting intracellular transcription factor BOB1. Blood. 2017;129(10):1284–95.CrossRefPubMed
89.
Mastaglio S, Genovese P, Magnani Z, Ruggiero E, Landoni E, Camisa B, et al. NY-ESO-1 TCR single edited central memory and memory stem T cells to treat multiple myeloma without inducing GvHD. Blood. 2017;08:732636. Blood-2016. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​28637663. Accessed 10 Jul 2017.
90.
•• Noonan KA, Huff CA, Davis J, Lemas MV, Fiorino S, Bitzan J, et al. Adoptive transfer of activated marrow-infiltrating lymphocytes induces measurable antitumor immunity in the bone marrow in multiple myeloma. Sci Transl Med. 2015;7(288):288ra78. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​25995224. Accessed 4 Apr 2017. Clinical evidence of immune response from re-infused aMILs to treat MM.
91.
Mihara K, Bhattacharyya J, Kitanaka A, Yanagihara K, Kubo T, Takei Y, et al. T-cell immunotherapy with a chimeric receptor against CD38 is effective in eliminating myeloma cells. Leukemia. 2012. Macmillan Publishers Limited. 26(2):365–7. doi:10.​1038/​leu.​2011.​205. Accessed 20 Sep 2015.
92.
Drent E, Groen RWJ, Noort WA, Themeli M, Lammerts van Bueren JJ, Parren PWHI, et al. Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma. Haematologica. 2016;101(5):616–25. doi:10.​3324/​haematol.​2015.​137620. Accessed 12 Apr 2017.
93.
94.
95.
Casucci M, Nicolis di Robilant B, Falcone L, Camisa B, Norelli M, Genovese P, et al. CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma. Blood. 2013;122(20):3461–72. doi:10.​1182/​blood-2013-04-493361. Accessed 5 Apr 2017.
96.
Peinert S, Prince HM, Guru PM, Kershaw MH, Smyth MJ, Trapani JA, et al. Gene-modified T cells as immunotherapy for multiple myeloma and acute myeloid leukemia expressing the Lewis Y antigen. Gene Ther. 2010;17(5):678–86. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​20200563. Accessed 5 Apr 2017.
97.
98.
99.
Klebanoff CA, Scott CD, Leonardi AJ, Yamamoto TN, Cruz AC, Ouyang C, et al. Memory T cell–driven differentiation of naive cells impairs adoptive immunotherapy. J Clin Invest. 2015;126(1):318–34. American Society for Clinical Investigation. Available from: https://​www.​jci.​org/​articles/​view/​81217. Accessed 5 Apr 2017.
100.
Sommermeyer D, Hudecek M, Kosasih PL, Gogishvili T, Maloney DG, Turtle CJ, et al. Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo. Leukemia. 2015;30(2):492–500. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​26369987. Accessed 12 Apr 2017.
101.
102.
103.
Pegram HJ, Purdon TJ, van Leeuwen DG, Curran KJ, Giralt SA, Barker JN, et al. IL-12-secreting CD19-targeted cord blood-derived T cells for the immunotherapy of B-cell acute lymphoblastic leukemia. Leukemia. 2015;29(2):415–22. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​25005243. Accessed 31 Mar 2015.
104.
Curran KJ, Seinstra BA, Nikhamin Y, Yeh R, Usachenko Y, van Leeuwen DG, et al. Enhancing antitumor efficacy of chimeric antigen receptor T cells through constitutive CD40L expression. Mol Ther. 2015;23(4):769–78. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​25582824. Accessed 23 Jun 2015.
105.
106.
Cherkassky L, Morello A, Villena-Vargas J, Feng Y, Dimitrov DS, Jones DR, et al. Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. J Clin Invest. 2016;126(8):3130–44. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​27454297. Accessed 4 Apr 2017.
107.
Metadaten
Titel
Novel Immunotherapies for Multiple Myeloma
verfasst von
Mattia D’Agostino
Mario Boccadoro
Eric L. Smith
Publikationsdatum
18.08.2017
Verlag
Springer US
Erschienen in
Current Hematologic Malignancy Reports / Ausgabe 4/2017
Print ISSN: 1558-8211
Elektronische ISSN: 1558-822X
DOI
https://doi.org/10.1007/s11899-017-0397-7

Weitere Artikel der Ausgabe 4/2017

Current Hematologic Malignancy Reports 4/2017 Zur Ausgabe

Health Economics (N Khera, Section Editor)

Patterns of Care and Survival for Elderly Acute Myeloid Leukemia—Challenges and Opportunities

B-cell NHL, T-cell NHL, and Hodgkin Lymphoma (D Persky, Section Editor)

An Update on the Use of Immunotherapy in the Treatment of Lymphoma

Health Economics (N Khera, Section Editor)

Equal Treatment and Outcomes for Everyone with Multiple Myeloma: Are We There Yet?

CART and Immunotherapy (M Ruella, Section Editor)

Targeting Immune System Alterations in Hodgkin Lymphoma

CART and Immunotherapy (M Ruella, Section Editor)

Considerations in T Cell Therapy Product Development for B Cell Leukemia and Lymphoma Immunotherapy

B-cell NHL, T-cell NHL, and Hodgkin Lymphoma (D Persky, Section Editor)

Therapeutic Options for Aggressive T-Cell Lymphomas

Neu im Fachgebiet Onkologie

18.04.2024 | Wirbelsäulenmetastase | Nachrichten

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

17.04.2024 | Mammakarzinom | Nachrichten

Adjuvante Brustkrebstherapie: Doppelt hält besser

16.04.2024 | Maligne primäre ZNS-Tumoren | Nachrichten

Manche Gestagene können das Risiko für Meningeome erhöhen

10.04.2024 | PSA-Screening | Nachrichten

Einladung zum PSA-Screening senkt die Krebssterblichkeit
weitere anzeigen

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen